NCT01130246终止3 期
VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 5,189
- 试验地点
- 361
- 主要终点
- Primary Objective of the Study
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
详细描述
A double-blind randomized parallel group placebo controlled study in subjects presenting with an ACS. Up to 6500 subjects will be randomized to receive either A-002 500 mg once daily (QD) or placebo tablets in addition to atorvastatin QD and standard of care. Treatment will be 16 weeks in duration. The dose of atorvastatin shall be adjusted after 8 weeks if subject's LDL-C is ≥100 mg/dL, but otherwise must remain stable throughout the16-week duration of study. The survival status for all enrolled subjects will be ascertained 6 months after they complete the study.
Randomization must occur within ≤96 hours of hospitalization for the index ACS event, or if already hospitalized, within ≤96 hours of index event diagnosis. Follow-up visits will occur on Weeks 1, 2, 4, 8, and 16. A 6 month follow-up visit will also occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥40 years of age
- •Written informed consent from the subject
- •A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI)
- •Unstable angina is defined as:
- •Chest pain symptomatic of ischemia or angina occurring at rest or on minimal exertion with a pattern of increasing frequency or severity, lasting >10 minutes and consistent with myocardial ischemia within 24 hours prior to hospitalization and
- •New or dynamic ST-segment depression or prominent T-wave inversion changes in at least 2 contiguous leads and
- •In addition subjects meeting the above criteria for unstable angina must also have either troponin I, troponin T or CKMB above the LLD but below the 99th percentile of the upper reference limit (URL) and not due to cardioversion or underlying cardiovascular (CHF, cardiomyopathy) or renal disease
- •NSTEMI is defined as:
- •Chest pain symptomatic of ischemia
- •No electrocardiogram (ECG) changes, or ST-depression, or T wave changes(i.e., no new Q waves on serial ECGs)and
- •Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB isoenzyme > URL
- •STEMI is defined as:
- •Chest pain symptomatic of ischemia
- •ST segment elevation and associated T wave changes or ST-segment elevation of at least 2 mm in 2 contiguous leads, either of which persisting for longer than 15 minutes and
- •Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB >URL
- •All subjects must have the presence of at least one of the following risk factors:
- •Diabetes Mellitus or
- •Presence of any 3 of the following characteristics of metabolic syndrome
- •Waist circumference >102 cm in males, >88 cm in females
- •Serum triglycerides ≥150 mg/dL (≥1.7 mmol/L)
- •HDL-C <40 mg/dL (<1 mmol/L) in males, <50 mg/dL (<1.3 mmol/L) in females
- •Blood pressure ≥130/85 mmHg
- •Plasma glucose ≥110 mg/dL (≥6.1 mmol/L) or
- •history of cerebrovascular disease (stroke or TIA) or
- •history of peripheral vascular disease or
- •previous CABG or
- •previous documented myocardial infarction or
- •previous coronary revascularization
- •Subjects must be randomized within ≤96 hours of hospital admission for the index event, or if already hospitalized, within ≤96 hours of index event diagnosis
- •Revascularization, if required or planned, must occur prior to randomization
排除标准
- •Subjects enrolled in another experimental (interventional)protocol within the past 30 days prior to Screening.
- •Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision or radiation therapy (e.g. chemotherapy)
- •The presence of any severe liver disease with cirrhosis, active hepatitis, active chronic hepatitis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x ULN, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
- •Active cholecystitis, gall bladder symptoms, or any hepatobiliary abnormalities
- •The presence of severe renal impairment (creatinine clearance [CrCl] <30 mL/min or creatinine >3 x ULN),nephrotic syndrome, or subjects undergoing dialysis
- •Uncontrolled diabetes mellitus (known hemoglobin A1c [HbA1c] >11% within the last 1 month prior to Screening)
- •Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or females of childbearing potential who have a positive pregnancy test during screening evaluation. Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double barrier method (diaphragm with spermicidal foam or jelly, or a condom).
- •Subjects who have a history of alcohol or drug abuse within 1 year of study entry
- •Subjects living too far from participating center or unable to return for follow-up visits
- •Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
- •Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection
- •Acute bacterial, fungal or viral infection
- •Subjects currently taking drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
- •Subjects with New York Heart Association (NYHA) Class III or IV heart failure, or if known, left ventricular ejection fraction (LVEF) <30
- •Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation
- •Ventricular arrhythmias requiring chronic drug treatment or implantable cardioverter-defibrillator (ICD)
- •Subjects with no stenosis or stenosis <50% on angiography, if known
- •Subjects with a pacemaker or persistent left bundle branch block (LBBB)
- •Fasting triglyceride levels of ≥400 mg/dL (4.5 mmol/L)
- •Subjects who have a history of statin intolerance or a significant myopathy or rhabdomyolysis with any lipid altering drugs
- •Subjects currently treated with the maximum labeled dose of a statin and not at LDL-C target for their level of risk as defined by NCEP ATP III
研究组 & 干预措施
A-002 500 mg
Experimental
Once daily oral administration
干预措施: A-002, varespladib methyl (Drug)
Matched Placebo
Placebo Comparator
Once daily oral administration
干预措施: Placebo (Drug)
结局指标
主要结局
Primary Objective of the Study
时间窗: 16 weeks
To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization.
次要结局
- Secondary Objective of the Study(2, 4, 8, 16 weeks and 6 months)
研究者
研究点 (361)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanChronic Hepatitis CNCT03020095Ascletis Pharmaceuticals Co., Ltd.38
已完成
1 期
Pilot Study of AVT16 in Healthy Adult SubjectsHealthyNCT06400719Alvotech Swiss AG18
招募中
1 期
The Safety and Effectiveness of NV-A01 in Glioma PatientsAdvanced Glioblastoma PatientsNCT06193538First Affiliated Hospital of Wannan Medical College15
已完成
2 期
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee PainPainOsteoarthritisNCT02104050Olatec Therapeutics LLC202
已完成
4 期
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.HypertensionNCT00698646Novartis Pharmaceuticals384